Tech Company Financing Transactions
ArsenalBio Funding Round
Euclidean Capital, Kleiner Perkins Caufield & Byers and Osage Partners participated in a $85 million Series A funding round for ArsenalBio. This VC investment round was announced by the company on 10/18/2019.
Transaction Overview
Company Name
Announced On
10/18/2019
Transaction Type
Venture Equity
Amount
$85,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
571 Eccles Ave.
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Overview
ArsenalBio is building a programmable cell therapy company to create highly effective and accessible immune cell therapies to impact outcomes for a much broader number of patients, initially those with cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ken Drazan
Chief Scientific Officer
Jane Grogan
Chief Technical Officer
Tarjei Mikkelsen
VP - R & D
Michael Kalos
Browse more venture capital transactions:
Prev: 10/18/2019: Winnow Solutions venture capital transaction
Next: 10/18/2019: Invoca venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs